The U.S. Food and Drug Administration (FDA) announced a voluntary recall of Chantix, also known as varenicline, a widely used medication to help people quit smoking. The action followed testing that found “elevated levels of nitrosamines” in some batches.

Nitrosamines are chemicals found naturally in certain foods and water, but they can be dangerous in higher amounts. Long-term exposure to these compounds “has been linked to an increased risk of cancer,” which is why regulators treat them seriously.

In this case, the detected levels were above the FDA’s safety limit. While the exact risk to patients is still under review, officials stressed that precautionary steps are necessary to protect public health. The recall is “voluntary,” meaning it was carried out in cooperation with the manufacturer to remove affected products.

Chantix has long been considered one of the most effective treatments for quitting smoking, so its temporary absence may create difficulties for some patients. Healthcare providers are being urged to contact those who may have received affected batches.

Patients currently taking the medication are advised not to panic but to consult their doctors or pharmacists about alternatives. At the same time, the FDA is pushing for stronger testing standards across the pharmaceutical industry, noting that similar recalls have happened before.

Officials emphasize that even if risks appear low or uncertain, safety comes first. The recall reflects the agency’s ongoing effort to maintain trust and ensure the safety of medications.